REMSleep Holdings, Inc. is a Nevada-based medical technology company focusing on sleep apnea treatment solutions, notably the DeltaWave CPAP interface, with patent protections, pending clinical trials, and growing market potential.

# REMSleep Holdings, Inc. - Company Summary

## Business Overview
REMSleep Holdings, Inc. is a Nevada-incorporated medical technology company focused on developing and commercializing innovative solutions for the treatment of obstructive sleep apnea (OSA). The company's primary product is the DeltaWave CPAP interface, an ergonomic nasal-pillows device designed to improve comfort and compliance in sleep apnea therapy.

## Product Details
- **DeltaWave CPAP Interface:** A nasal-pillows type interface that addresses common issues such as work of breathing, claustrophobia, sinus dryness, and the need for less driving pressure.
- **Patents:**
  - Utility patent (U.S. Patent No. 10987481) awarded April 27, 2021, for the DeltaWave device.
  - Design patent (D1,017,025 S) awarded March 5, 2024.
- **Development:** The company plans to conduct clinical trials upon securing adequate financing. 

## Market and Industry
- The sleep treatment industry is significant, with a global market valued at nearly $8 billion in 2011, projected to reach approximately $19.72 billion by 2017.
- In the U.S., over 8 million CPAP interfaces are sold annually; an estimated 80 million people worldwide have undiagnosed sleep apnea.
- The industry faces high dropout rates, with over 50% of patients discontinuing CPAP therapy within six months due to discomfort and work of breathing.
- The market is increasingly moving towards ergonomic, user-friendly devices and home-based diagnostics.

## Customers and Users
- **Target Markets:** Sleep product distributors, home care dealers, private sleep labs, physicians (especially sleep physicians), medical groups, hospitals, and medical associations.
- **End Users:** Patients requiring sleep apnea treatment, with most revenue expected from home care and hospital markets.

## Operations
- Manufacturing is outsourced to mold makers with molds made in China; consideration is being given to relocating manufacturing to the U.S.
- Operations are entirely dependent on securing adequate financing.

## Employees
- The company currently employs:
  - Thomas J. Wood (Chief Executive Officer) 
  - John Lane (Chief Technology Officer)
- All other services are provided by independent contractors.

## Financial Highlights
- **Revenue:** Recognized $117,185 in 2024, down from $203,718 in 2023.
- **Cost of Goods Sold:** $99,147 in 2024, significantly lower than $960,457 in 2023 (which included inventory impairment expense).
- **Net Income/Loss:** 
  - Loss of $1,077,997 in 2024.
  - Loss of $1,777,838 in 2023.
- **Revenue from Sales:** Mainly from CPAP systems, with ongoing product development costs.
- **Assets:** Approximately $591,697 as of December 31, 2024.
- **Liabilities:** Total liabilities of $254,994 as of December 31, 2024, including accounts payable and convertible notes payable.
- **Stockholders' Equity:** $336,703 as of December 31, 2024.
- The company is a smaller reporting company, with approximately 156 stockholders of record as of April 14, 2025.

## Additional Context
- The company’s ongoing operations are heavily dependent on securing further financing.
- It has received FDA 510(k) approval for its DeltaWave product as of July 2, 2024, with inventory readiness expected in Q2 2025.
- The company has patent protections for its DeltaWave product and plans to expand its sleep product portfolio.

REMSleep Holdings, Inc. is a medical device company dedicated to developing innovative sleep apnea solutions, particularly through its flagship product, DeltaWave.

# REMSleep Holdings, Inc. Overview

## Company Description
REMSleep Holdings, Inc. is a medical device company that focuses on developing and distributing innovative sleep apnea products. The primary product is the **DeltaWave**, a patent-pending CPAP (Continuous Positive Airway Pressure) interface designed to improve comfort and compliance for patients suffering from sleep apnea. 

### Key Features of DeltaWave:
- Does not disrupt normal breathing mechanics.
- Non-claustrophobic design.
- Causes zero "work of breathing" (WOB).
- Minimizes or eliminates drying of the sinuses.
- Requires less driving pressure.
- Allows users to feel safe and secure while sleeping.

## Business Background
- **Incorporated**: June 6, 2007, in Nevada.
- **Formerly Known As**: Bella Viaggio, Inc.; name changed to Kat Gold Holdings Corp. in 2010 and finally to REMSleep Holdings, Inc. in 2015.
- **Acquisition**: Acquired REMSleep LLC in January 2015, making it a wholly-owned subsidiary.
- **Officers' Experience**: 35 years of collective experience in the sleep industry.

## Market Opportunity
The sleep treatment and equipment market is substantial, with **$7.96 billion in 2011** and significant projected growth. An estimated **80 million** Americans suffer from undiagnosed sleep apnea, providing a vast potential customer base. Each year, over **8 million CPAP interfaces** are sold in the U.S., with many users abandoning treatment due to discomfort.

## Target Market
REMSleep's primary target market includes:
- Sleep product distributors
- Home care dealers
- Private sleep labs
- Physicians (especially sleep specialists)
- Hospitals
- Medical groups

### Customer Base
- Over **972,000** physicians and **365,000** doctors’ offices exist in the U.S.
- Nearly **5,800** hospitals operate as potential customers.
- Approximately **30,000** businesses serve the home healthcare market, generating **$59 billion** in annual revenue.

## Financial Overview
- **Employees**: Two full-time employees (Thomas J. Wood, CEO; John Lane, CTO) with additional services provided by independent contractors. Personnel will be added based on funding availability.
- **Revenue**: Specific revenue figures are not disclosed; however, most company revenues are expected to come from home care dealers and hospitals.
- **Financing Dependency**: All operational aspects—including manufacturing, marketing, and product development—are dependent on securing adequate financing. Failure to do so could lead to serious consequences, including potential bankruptcy.

## Manufacturing and Operations
- **Manufacturing**: Currently relies on mold makers in China with considerations to relocate manufacturing to the U.S.
- The entire operational strategy is contingent on obtaining necessary funding for production and marketing activities.

## Competitive Landscape
The company competes in a highly consolidated market with significant players such as:
- ResMed (45% market share)
- Philips Respironics (30%)
- Fisher & Paykel Healthcare (12%)

## Regulatory Compliance
REMSleep products must adhere to strict FDA regulations concerning safety and efficacy. The company's products are classified under **Class I or Class II** medical devices, requiring 510(k) pre-market notifications.

## Conclusion
REMSleep Holdings, Inc. operates in a burgeoning market, aiming to address significant compliance and comfort issues associated with traditional sleep apnea therapies. With substantial potential customer bases and ongoing advancements in their product line, the company stands poised for growth, though it remains at the mercy of securing adequate financing to realize its operational components.

RemSleep Holdings Inc.

10-K / April 14, 2025

10-K / April 16, 2024

10-K / April 14, 2025

REMSleep Holdings, Inc. - Company Summary

Business Overview

Product Details

Market and Industry

Customers and Users

Operations

Employees

Financial Highlights

Additional Context